Mestastop Solutions
Bengaluru
About Mestastop Solutions
Problem Statement: Most current drugs approved for metastatic cancer, responsible for 90% of deaths, increase survival by a meagre few months. Clinicians need molecules that will delay the tumours' spread and empower them with more time to treat localized cancer. Additionally, the current method of stratifying patients at higher risk of metastasis via the node status often does not work, surprising clinicians. The Solution: Mestastop has identified the gaps as to why anti-metastasis drug discovery failed and has created three proprietary platforms integrating cell biology, genetic engineering, machine learning, animal pharmacology and clinical sampling that do the following: 1. Identifies the rate-limiting steps of metastasis, thereby discovering novel first-in-class targets 2. Screening platform to identify compounds that abrogate the rate-limiting steps 3. Screening platform that identifies the effect of approved drugs on the process of metastasis 4. Predicting the metastatic probability of a treatment-naive primary tumour patient with no second lesion
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $714.4K
- Funding stage: Seed
- Last round: Seed (Oct 2023)
- Website: mestastop.com
- Phone: 9177884450
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/mestastop-solutions-106950 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.